Sale disclosed
David Kirn
See Remarks
Common Stock
- Reported value
- $750.24K
- Reported price
- $12.9215 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
4D Molecular Therapeutics, Inc.
Last 30 daysNo qualifying insider buying. Sales: $1.59M by 2 insiders.
Showing the first 6 of 18 trades on this page.
See Remarks
Common Stock
See Remarks
Common Stock
Chief Legal Officer
Common Stock
See Remarks
Common Stock
Chief Legal Officer
Common Stock
See Remarks
Common Stock
See Remarks
Common Stock
Chief Legal Officer
Common Stock
Chief Legal Officer
Common Stock
See Remarks
Common Stock
See Remarks
Common Stock
See Remarks
Common Stock
See Remarks
Common Stock
See Remarks
Common Stock
Chief Legal Officer
Common Stock
Chief Legal Officer
Common Stock
See Remarks
Common Stock
See Remarks
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| See Remarks | Common StockSale10b5-12 trades | 58,333avg $12.92 / share | $753.94K | Oct 5Filed Oct 7 · 2d later | 2 filings
|
| Chief Legal Officer | Common StockSale10b5-1 | 1,635$13.65 / share | $22.32K | Sep 16Filed Sep 22 · 6d later | SEC filing |
| See Remarks | Common StockSale10b5-1 | 58,333$13.90 / share | $811K | Sep 14Filed Sep 16 · 2d later | SEC filing |
| Chief Legal Officer | Common StockSale10b5-1 | 584$14.00 / share | $8.18K | Sep 1Filed Sep 3 · 2d later | SEC filing |
| See Remarks | Common StockSale10b5-12 trades | 69,076avg $15.75 / share | $1.09M | Aug 19Filed Aug 21 · 2d later | 2 filings
|
| Chief Legal Officer | Common StockSale10b5-1 | 1,635$12.00 / share | $19.62K | Aug 13Filed Aug 17 · 4d later | SEC filing |
| Chief Legal Officer | Common StockSale10b5-1 | 1,635$12.20 / share | $19.95K | Aug 17Filed Aug 17 · 0d later | SEC filing |
| See Remarks | Common StockSale10b5-1 | 26,842$10.23 / share | $274.6K | Aug 4Filed Aug 5 · 1d later | SEC filing |
| See Remarks | Common StockSale10b5-1 | 12,415$10.05 / share | $124.72K | Aug 3Filed Aug 4 · 1d later | SEC filing |
| See Remarks | Common StockSale10b5-1 | 42,608$12.87 / share | $548.18K | Jul 9Filed Jul 14 · 5d later | SEC filing |
| See Remarks | Common StockSale10b5-12 trades | 15,725avg $12.03 / share | $189.23K | Jul 10Filed Jul 14 · 4d later | 2 filings
|
| Chief Legal Officer | Common StockSale10b5-1 | 6,566$14.00 / share | $91.92K | Jun 30Filed Jul 2 · 2d later | SEC filing |
| Chief Legal Officer | Common StockSale10b5-1 | 9,810$12.00 / share | $117.72K | Jun 23Filed Jun 25 · 2d later | SEC filing |
| See Remarks | Common StockSale10b5-1 | 114,746$10.47 / share | $1.2M | Jun 22Filed Jun 23 · 1d later | SEC filing |
| See Remarks | Common StockSale10b5-1 | 1,922$10.02 / share | $19.26K | Jun 1Filed Jun 2 · 1d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.